亨迪藥業(301211.SZ):米力農注射液獲得藥品註冊證書
格隆匯8月14日丨亨迪藥業(301211.SZ)公佈,公司於近日收到國家藥品監督管理局(以下簡稱"國家藥監局")核准簽發的《藥品註冊證書》,藥品名稱為米力農注射液。
米力農注射液是一種正性肌力藥物和血管擴張劑,在產生正性肌力作用和擴血管作用的濃度下,米力農注射液為心肌和血管平滑肌 cAMP磷酸二酯酶第三峯同功酶的選擇性抑制劑,適用於急性失代償性心力衰竭患者的短期靜脈治療。
公司米力農注射液獲得國家藥監局的藥品註冊證書,標誌着公司具備了在國內市場銷售該藥品的資格,進一步豐富了公司的產品線,同時也標誌着公司的"原料藥製劑一體化"戰略有了新的突破點。根據國家相關政策,通過一致性評價的藥品品種在醫保支付及醫療機構採購等領域將獲得更大的支持力度。公司的米力農注射液通過仿製藥一致性評價,提升了自身的競爭能力,有利於上市銷售後取得較大的市場份額。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.